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A B S T R A C T
Identification of Parkinson's disease at the earliest possible stage of the disease may provide the best opportunity
for the use of disease modifying treatments. However, diagnosing the disease during the pre-symptomatic period
remains an unmet goal. To that end, we used pharmacological MRI (phMRI) to assess the function of the cortico-
basal ganglia circuit in a non-human primate model of dopamine deficiency to determine the possible re-
lationships between phMRI signals with behavioral, neurochemical, and histological measurements. Animals
with unilateral treatments with the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), that
expressed stable, long-term hemiparkinsonism were challenged with the dopaminergic receptor agonist, apo-
morphine, and structure-specific phMRI blood oxygen level-dependent (BOLD) activation responses were
measured. Behavioral, histopathological, and neurochemical measurements were obtained and correlated with
phMRI activation of structures of the cortico-basal ganglia system. Greater phMRI activations in the basal
ganglia and cortex were associated with slower movement speed, decreased daytime activity, or more pro-
nounced parkinsonian features. Animals showed decreased stimulus-evoked dopamine release in the putamen
and substantia nigra pars compacta and lower basal glutamate levels in the motor cortex on the MPTP-lesioned
hemisphere compared to the contralateral hemisphere. The altered neurochemistry was significantly correlated
with phMRI signals in the motor cortex and putamen. Finally, greater phMRI activations in the caudate nucleus
correlated with fewer tyrosine hydroxylase-positive (TH+) nigral cells and decreased TH+ fiber density in the
putamen. These results reveal the correlation of phMRI signals with the severity of the motor deficits and pa-
thophysiological changes in the cortico-basal ganglia circuit.
1. Introduction
Identification of Parkinson's disease (PD) at the earliest possible
stage of the disease may provide the best opportunity for the use of
disease modifying treatments. However, correctly diagnosing the dis-
ease during the pre-symptomatic period remains difficult. This is, in
part, because of the absence of predictive, non-invasive, in vivo tests for
PD and because PD symptoms resemble symptoms of other neurological
conditions. Moreover, the prevalence of both parkinsonian symptoms
and PD, per se, increases with age. The ideal diagnostic test would
confirm the presence of prodromal PD and provide some information
about the lead time to motoric symptoms and the rate of progression.
Pharmacological MRI (phMRI) has been increasingly used as a
neuroimaging technique to investigate region-specific brain activity
associated with the administration of CNS-active drugs (Breiter et al.,
1997; Grasby et al., 1993; Lahti et al., 1995). As an imaging modality,
phMRI has a number of advantages related to molecular, structural, and
functional neuroimaging that are rapidly expanding the neurobiological
understanding of the complexities of PD. phMRI holds the promise of
providing early indications of the pharmacodynamic activity of novel
CNS-targeted compounds in a safe, non-invasive manner through blood
oxygenation level dependent (BOLD) imaging in experimental animals
(Andersen et al., 2015; Zhang et al., 2018), and in humans (Barber
et al., 2017; Nemoto et al., 2017). As a result, significant effort has been
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devoted to implementing phMRI as a translational research tool to
develop novel CNS compounds (Bifone and Gozzi, 2012; Wise and
Tracey, 2006) and to study neurological disorders (Andersen et al.,
2015; Seibyl et al., 2012; Weiller et al., 2006). Drug-induced pharma-
codynamic responses detected from alterations in BOLD signals or re-
lative cerebral blood volume/flow (rCBV/rCBF) can serve as imaging
biomarkers to delineate the central effect of drug actions
(Bhattacharyya et al., 2017; Ghariq et al., 2014; Jann et al., 2015; Tak
et al., 2015). In addition, phMRI has been used to study several key
neurotransmitter systems. Collectively, these studies have highlighted
the value of phMRI to elucidate neurobiological mechanisms of drug
actions to gain a better understanding of PD (Seibyl et al., 2012).
However, the clinical use of phMRI techniques as a tool for the early
diagnosis and clinical progression of PD is still lagging compared with
other modalities like positron emission tomography (PET) or single
photon emission computed tomography (SPECT), possibly because the
underlying neurophysiological mechanism(s) of phMRI signals are not
fully understood. Consequently, determining the relationships between
phMRI BOLD-activation and disease-related changes in neurobiology
and neurophysiology may lead to a more integrated and comprehensive
understanding of PD (Weingarten et al., 2015). Pharmacological neu-
roimaging as it relates to dopamine terminal degeneration could serve
important and unique roles in both earlier and later stages of the dis-
ease. In the early stages, neuroimaging might potentially allow diag-
nosis in the prodromal state. In the later stages, it might help with
elucidating pathology relevant to new drug development.
In the present study, the nonselective dopamine D1/D2 receptor
agonist apomorphine (APO; currently used as an FDA-approved PD
treatment) was used to stimulate the dopaminergic systems in animals
with stable, long-term MPTP-induced parkinsonism. The phMRI re-
sponses in the cortico-basal-ganglia-cortical circuit were directly cor-
related with a variety of in vivo measurements including behavioral
responses, in vivo microdialysis measurements of dopamine (DA)
function, and electrochemical recordings of resting glutamate levels.
Additional comparisons were made with postmortem data including
dopaminergic neuron counts in the substantia nigra (SN) pars compacta
(SNc) and fiber density in the striatum. These experiments were all
designed to test the hypothesis that phMRI signals (BOLD responses)
correlate with the severity of the motor deficits and pathophysiological
changes in the nigrostriatal system and could be used as an indicator of
biological processes that change in response to dysfunction within the
cortico-basal-ganglia-cortical circuit.
2. Methods and materials
2.1. Animals
All procedures used in the study were approved by the University of
Kentucky Institutional Animal Care and Use Committee and followed
NIH and USDA guidelines. Six, late middle-aged (18 to 22 years old),
female rhesus monkeys (Macaca mulatta) expressing long-term hemi-
parkinsonism were used in the study. All animals were originally ob-
tained from a commercial supplier (Covance, Alice, TX) and were
housed in a temperature-controlled room and maintained on a 12-h
light and 12-h dark cycle. Throughout the entire study, water was
available ad libitum and standard non-human primate biscuits were
supplemented daily with fresh fruits and vegetables.
Data were obtained within an 18-month period, approximately
3.5 years after the animals had been rendered hemiparkinsonian by a
unilateral administration of 0.12mg/kg MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) via the right carotid artery. After MPTP
administration, all animals developed mild to moderate parkinsonian
features including bradykinesia, rigidity of upper and lower limbs on
the affected side, stooped posture, and mild postural instability. Some
data shown here were previously reported and are recounted here to
describe the behavioral, histological, and neurochemical deficits of
these animals and provide the basis for correlative analyses.
2.2. Behavioral evaluation
All animals were extensively monitored and evaluated by non-
biased, objective, and non-invasive methods including an automated
video-tracking system (EthoVision Pro, Noldus Technologies, Asheville,
NC) and Actical accelerometers (MiniMitter, Bend, OR). Automated
Movement Tracking. The detailed procedures have been described else-
where (Ding et al., 2008; Luan et al., 2008; Walton et al., 2006; Xin
et al., 2008). Briefly, video recording procedures were conducted in
specially-designed cages located in a room adjacent to the housing
quarters. The tracking method relies on calibrating the software to the
dimensions of the cage, so that the position of the animal can be de-
termined in the cage based on (x,y,z) coordinates. Behavioral values,
including distance traveled (cm) and movement velocity (cm/s) were
measured over the course of one hour. The same coded video records
were also used by trained observers to blindly evaluate parkinsonian
features using our nonhuman primate parkinsonian rating scale (Ding
et al., 2008; Ovadia et al., 1995). Actical accelerometers. Changes in
overall home-cage activity level were continuously monitored for each
monkey using activity monitors worn on collars. The monitors were
programmed to measure and store the activity counts at a one-minute
sample interval. Daily activity counts were recorded from 06 h00 (lights
ON) to 18 h00 (lights OFF) and nighttime levels were measured from
18 h00 to 06 h00.
2.3. Pharmacological MRI (phMRI)
Based on previously published procedures (Zhang et al., 2018), all
images were acquired on a Siemens 3 T Trio clinical MRI system using a
dedicated receive-only coil for reception, which was designed and de-
veloped by our group. Animals were maintained under general an-
esthesia (~1% isoflurane in oxygen) during image acquisitions. The
BOLD-effect weighted MR images used to measure the phMRI response
were acquired in an anatomically coronal plane. The image planes of
the acquisition were arranged to cover the motor cortex and the basal
ganglia. A segmented gradient-echo EPI sequence with TE= 28ms and
a turbo factor of 7 was used to reduce echo train length and minimize
susceptibility-related artifacts. The EPI sequence acquisition parameters
are FOV=112×98 mm and image matrix 64×56 for an in-plane
resolution of 1.75mm. A total of 15 contiguous slices, each 2mm-thick,
were acquired at a rate of 15 s per EPI volume. The overall scan
duration was 80min with 128 volumes acquired prior to APO admin-
istration (0.1 mg/kg injection S.C.) as a baseline and 192 volumes ac-
quired after APO to track the response. APO was prepared daily in 0.9%
sterile saline 2 h before the scan. Images were motion corrected and
spatially smoothed using a Gaussian kernel of width 3.5 mm. phMRI
response was calculated as the fractional signal change in % of the
average of the post-APO image data relative to the pre-APO baseline. A
co-registered high-resolution (0.67×0.67×1mm) T1-weighted ana-
tomical MRI scan was acquired in each session for spatial localization of
the activation response.
2.4. In vivo microdialysis of dopamine overflow
Measurement of both potassium- and d-amphetamine-induced DA
release was collected following previously published procedures from
each animal, after the PD features were fully developed and stable (Cass
et al., 2007; Gerhardt et al., 2002; Grondin et al., 2003). Briefly,
custom-made CMA 11 dialysis probes with a membrane length of
3.0 mm and diameter of 0.24mm (CMA Microdialysis, North Chelms-
ford, MA) were slowly lowered under sterile conditions into the pu-
tamen or SNc using MRI-derived stereotactic coordinates for each an-
esthetized animal. The probes were perfused at a flow rate of 1.2 μl/min
with artificial CSF, and dialysate fractions were collected at 30-min
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intervals. After a 1-h equilibration period, two baseline fractions were
collected and then overflow of DA was locally stimulated by reverse
microdialysis by switching to a perfusate solution containing elevated
potassium (100mM) for a single 30-min fraction, then switching back
to the original perfusate for three additional fractions. A d-ampheta-
mine (250 μM) stimulation was then included in the perfusate for one
30-min fraction followed by three final fractions with normal artificial
CSF. Dialysate samples were assayed for DA after collection using HPLC
with electrochemical detection (Cass et al., 2003). Dialysis probe pla-
cement was confirmed in each animal by structural MRI within 48–72 h
post-surgery.
Basal levels of DA were defined as the average value of the two
fractions preceding stimulation by excess potassium. All probes were
calibrated in vitro prior to use to determine acceptable probes (recovery
of DA at least 15%). However, values were not corrected for in vitro
recoveries, as uncorrected values may be better correlated to true va-
lues (Glick et al., 1994). Dialysis data were expressed as nM con-
centration of DA or metabolite in the dialysate and, for evoked over-
flow, as the total amount of DA in the dialysate above baseline after
stimulation with potassium or d-amphetamine.
3. Electrochemical recordings of basal levels of glutamate
Based on previously published procedures (Fan et al., 2014;
Quintero et al., 2007), the resting levels of glutamate were measured,
with biosensors, bilaterally in the primary motor cortex covering the
trunk and upper body regions (Fig. 4a) on the same day as necropsy.
Under general anesthesia (~1% isoflurane in oxygen), the skull directly
over the primary motor cortex was removed bilaterally to allow access
to the biosensors and a reference electrode (a Ag/AgCl electrode, Model
RE-5B, Bioanalytical Systems, West Lafayette, IN) was inserted into a
remote pocket (5 mm×50mm) in the area above the occipital lobes so
as to not interfere with the biosensors. Five different points (2–3mm
apart) from medial to lateral primary motor cortex were used on each of
the left and right sides of the cortex as illustrated in Fig. 4a. Resting
glutamate values for the right (MPTP-lesioned) and left cortices were
generated from an average of the last 30 s of the equilibration period.
3.1. Post-mortem morphology
Immediately after the glutamate recordings, all animals were deeply
anesthetized with pentobarbital (20–25mg/kg, IV) and euthanized via
transcardial perfusion with 0.9% saline based on previously published
procedures (Ding et al., 2008; Gash et al., 1996). The brains were im-
mediately removed, immersion-fixed in 4% paraformaldehyde solution
in 0.1 M phosphate buffer (pH 7.4) overnight and cryoprotected in 30%
buffered sucrose until they sank. Then, 40 μm-thick sections were cut
on a sliding microtome through the SN. Sections were processed for
tyrosine hydroxylase (TH, monoclonal antibody, 1:1000; Chemicon
International, Temecula, CA, USA) for assessment of TH-positive (TH+)
neuronal loss in the midbrain and loss of TH+ fibers in the striatum
(procedures described elsewhere, Ding et al., 2008; Gash et al., 1996;
Grondin et al., 2002). The number of TH+ midbrain dopaminergic
neurons was estimated bilaterally using an optical fractionator method
for unbiased stereological cell counting. In addition, TH+ fiber density
was measured as percentage of area with TH+ immunoreactive staining
in both sides of the caudate nucleus and putamen of each hemisphere
and in each animal.
3.2. Statistical analysis
Statistical comparisons between the right (MPTP-lesioned) and left
hemispheres were treated as un-paired measurements as MPTP treat-
ment profoundly affects the structure and physiology of the effected
hemisphere (Ding et al., 2008; Hamadjida et al., 2018). The phMRI data
used in the linear regression and correlation analyses were from the
hemisphere (right) on the ipsilateral side of MPTP administration. All
linear regressions were first order, and two-tailed Pearson correlations
were used to identify relationships among behavioral, phMRI, or resting
glutamate features. Glutamate resting levels were analyzed from time-
series recordings in individual animals using custom MatLab®-based
analysis software, averaged from the multiple points in each animal,
and compared among animals at the group level using a Student's t-test.
The in vivo microdialysis results were initially analyzed using an
ANOVA followed by Newman–Keuls post hoc comparisons for the DA
response at individual time points. All statistical analyses were
Fig. 1. phMRI activation in different structures between the MPTP-lesioned and unlesioned hemispheres. (A) caudate nucleus, (B) putamen, (C) primary motor
cortex, and (D) substantia nigra (SN). *p < 0.05, ** p < 0.01.
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conducted using Prism 6 or 7 GraphPad Software (San Diego, CA).
Differences of p < 0.05 were considered significant.
4. Results
4.1. Dynamic phMRI response to APO
APO-evoked activations were observed in the caudate nucleus
(Unlesioned: 0.95 ± 0.04% phMRI activation vs. MPTP-lesioned:
1.62 ± 0.02% phMRI activation; P < 0.01, Fig. 1A) and putamen
(Unlesioned: 0.47 ± 0.37% phMRI activation vs. MPTP-lesioned:
1.11 ± 0.36% phMRI activation; P < 0.01, Fig. 1B). BOLD activation
induced by the APO challenge in the primary motor cortex was lower
but not significantly different (Unlesioned: 2.38 ± 0.13% phMRI ac-
tivation vs. MPTP-lesioned: 2.12 ± 0.10% phMRI activation; P=0.1;
Fig. 1C). The second novel observation was the reduction of BOLD
activation induced by the APO challenge in the SN (Unlesioned:
1.09 ± 0.12% phMRI activation vs. MPTP-lesioned: 0.35 ± 0.04%
phMRI activation; P < 0.01; Fig. 1D). The result in the SN differs from
previous findings in short-term PD monkeys in which activation was
observed in the SN with lower doses of APO (Zhang et al., 2006).
4.2. Correlations with phMRI
4.2.1. Behavior
All animals exhibited stable motor deficits as judged by distance
traveled (Fig. 2A, Baseline: 10284 ± 503 cm vs. Post MPTP:
3060 ± 288 cm; P < 0.0001) and movement speed (Baseline:
2.9 ± 0.1 cm/s vs. Post MPTP: 1.5 ± 0.2 cm/s; P=0.0002). In addi-
tion, all animals showed a positive response to APO (Fig. 2B). The total
PD score on the nonhuman primate parkinsonian scale improved by
over 40% post APO administration (Fig. 2B, MPTP without APO:
4.0 ± 0.6 points vs. MPTP with APO: 2.3 ± 0.4 points; P=0.0075).
phMRI responses in the putamen were negatively correlated with the
distance traveled (r2=0.68, P=0.042) and the movement speed
(r2=0.69, P=0.039). Similar relationships were also identified be-
tween phMRI responses in the motor cortex and the daytime home-cage
activity (r2=0.76, P=0.02, Fig. 2C). APO-induced behavioral
changes in PD features were significantly correlated with APO-induced
phMRI responses in the putamen (r2=0.72, P=0.03, Fig. 2D), pre-
motor cortex (r2=0.80, P=0.015), and cingulate gyrus (r2=0.78,
P=0.018).
4.2.2. Histopathology
A novel observation was the heterogeneous responses to APO
challenge in the putamen on the ipsilateral side of MPTP administration
(Fig. 3A). The greatest responses to APO in the MPTP-lesioned side
were observed in the more posterior sections (8–13) while the responses
in the last 2 sections (14–15) were smaller. Unbiased stereological cell
counts of TH+ dopamine neurons revealed> 85% loss of TH+ cells in
the MPTP-treated SN; and densitometry of TH+ fiber showed a sig-
nificant reduction of TH+ fibers density in the MPTP-treated putamen.
Only 16.9% of dopaminergic fibers remained compared with the con-
tralateral side. The loss of TH+ terminals in the putamen was hetero-
geneous as shown by a greater loss in the posterior than anterior sec-
tions (Fig. 3B). The number of TH+ cells in the SNc was negatively
correlated with the phMRI-responses in the caudate nucleus (r2=0.75,
P=0.026, Fig. 3C). In addition, TH+ fiber densities in the lesioned
putamen (r2=0.80, P=0.016, Fig. 3D) and caudate nucleus
(r2=0.66, P=0.048) were significantly correlated with phMRI-re-
sponses seen in the primary motor cortex.
4.2.3. Neurochemistry
The average of individual resting basal glutamate (5 sample sites in
each hemisphere) in the motor cortex was significantly lower in the
MPTP-lesioned than the unlesioned hemisphere (Fig. 4A). Both po-
tassium- and d-amphetamine-evoked overflow of DA in the putamen
(Fig. 4B) and SNc (Fig. C) on the ipsilateral side of the lesion were lower
Fig. 2. (A) Distance traveled between baseline and
after MPTP lesion showed a significant (p < 0.001)
decrease in distance traveled after MPTP lesion. (B)
MPTP-treated animals showed characteristics asso-
ciated with dopamine deficiency as measured with a
parkinsonian rating scale. Long-term, stable parkin-
sonian features improved with apomorphine treat-
ment; **P < 0.01. (C) Home cage activity was in-
versely correlated with phMRI signals in the right
motor cortex. (D) Apomorphine-induced changes in
the parkinsonian rating scale was positively corre-
lated with BOLD activation in the right (MPTP-
treated side) putamen.
J.E. Quintero, et al. NeuroImage: Clinical 22 (2019) 101724
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than the contralateral side. Basal glutamate levels in the primary motor
cortex were significantly and negatively correlated with phMRI acti-
vation in the putamen (r2=0.87, P=0.0064, Fig. 4D) and in the
premotor cortex (r2=0.83, P=0.011). Both potassium- and d-am-
phetamine-evoked overflow of DA in the putamen (each measured for a
single time point, 30min after stimulus administration) had significant
correlations with phMRI responses in the putamen (data not shown).
Finally, d-amphetamine-evoked DA release in the SNc was found to
have a significant, negatively correlated relationship with the phMRI
motor cortex activation (r2= 0.74, P=0.027, Fig. 4E).
5. Discussion
Here, we used phMRI to assess the function of the cortico-basal
ganglia circuit in a non-human primate model of dopamine deficiency
to determine the possible relationships between phMRI signals and DA
dysfunction. Our study supports a direct relationship between BOLD-
responses and DA degeneration. First, BOLD-activation was highly
correlated with a number of measures, including: 1) potassium- and d-
amphetamine-evoked DA release in the putamen, 2) the number of
surviving TH+ cells in the SNc, and 3) TH+ fiber density in the pu-
tamen. Moreover, TH+ fibers density was also correlated with phMRI
responses in the putamen. These results are in line with those of a
previous phMRI study in parkinsonian rhesus monkeys (Zhang et al.,
2006)) in which phMRI responses to d-amphetamine were correlated
with surviving DA neurons in the midbrain. The results from this and
our previously published studies (Luan et al., 2008; Zhang et al., 2018;
Zhang et al., 2006) support the concept that phMRI could be a useful
tool for estimating the number of surviving DA neurons and terminals
in the nigrostriatal pathway, in a non-invasive manner. This could
provide pivotal information in assessing the disease state, the rate of
progressive cell loss rate, and the effects of a disease modifying therapy
over time.
BOLD-activation was also highly correlated with DA-related beha-
vioral deficits. Because the same dose of APO was used for phMRI and
behavioral testing, we believe that the APO-induced improvements in
parkinsonism may have occurred in parallel to the normalization of the
BOLD-signal in the motor cortex. (Hutchison et al., 1997; Stefani et al.,
1999; Stefani et al., 1997). Along these lines, human deep brain sti-
mulation (DBS) studies have shown that acute administration of APO
causes a significant decrease in cell firing activity, which is paralleled
by amelioration of PD hypokinesia as assessed by an intraoperatively-
administered Unified Parkinson's Disease Rating Scale (UPDRS) ex-
amination. In a previously published study, hemiparkinsonian monkeys
were treated with oral L-dopa (250 to 500mg) twice a day for 5 days.
We found that the treatment not only gradually and significantly re-
duced the initial L-dopa-induced rotational behavior (observed in the
immediate days following L-dopa), but that the treatment also sig-
nificantly reduced the amplitude of L-dopa-induced BOLD activations in
the putamen (Chen et al., 1999). In a human phMRI study, significant
correlations were demonstrated between the total motor UPDRS score
and BOLD activation in the striatum, subthalamic nucleus, external
segment of the globus pallidus and substantia nigra (Prodoehl et al.,
2010).
Another novel observation from the current study is that the BOLD
responses to APO administration were only observed in the putamen.
The heterogeneous BOLD response to APO matched the pattern of
heterogeneous changes of TH+ fibers in the putamen. This finding
suggests that the BOLD responses to APO in the putamen could reflect
the histopathological severity of degeneration of the DA system. In
humans, postmortem analyses demonstrate heterogeneous changes in
the putamen with the greatest reductions of dopamine uptake sites
measured by [3H] mazindol binding located in the medial putamen
(Porritt et al., 2005). In addition, [18F] dopa uptake detected by PET
showed more severe loss of functional integrity of the nigrostriatal
dopaminergic neurons in the posterior putamen in patients with PD. We
believe that these findings could be attributed to the organization of the
basal ganglia, which represents a complex extrapyramidal motor
system, as opposed to the pyramidal motor system (corticobulbar and
corticospinal pathways). The basal ganglia-thalamocortical circuits
maintain somatotopic organization of movement-related neurons
throughout the circuit mainly through the putamen while the caudate
Fig. 3. Areas of phMRI activation in the motor cortex
and basal ganglia in (A) after a 20min APO chal-
lenge. In the MPTP-lesioned side ( ), the pu-
tamen shows areas of higher APO-induced BOLD
activation along the rostral-caudal axis than in the
unlesioned side ( ). Sections were 3mm in
thickness through the putamen. *p < 0.05. (B) TH+
fiber density distribution along the anterior-posterior
plane of the putamen in the MPTP-lesioned and the
unlesioned hemispheres. (C) BOLD-responses in the
right (MPTP-lesioned side) caudate were negatively
correlated with the number of TH+ cells in the right
substantia nigra. (D) BOLD-responses in the right
motor cortex were negatively correlated with TH+
fibers in the right putamen.
J.E. Quintero, et al. NeuroImage: Clinical 22 (2019) 101724
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nucleus contributes to memory, learning, and cognitive functions, (for
reviews, see Alexander et al., 1986; Herrero et al., 2002). Moreover,
bradykinesia, which is a major clinical sign of PD, is more correlated
with the putamen than the caudate nucleus or SN (Prodoehl et al.,
2010).
In the current study, we selected late middle-aged animals because
PD is an age-associated neurodegenerative disease that infrequently
occurs before age 50 (Chu and Kordower, 2007; Ross et al., 2004;
Silver, 2006) with most patients being older than 60 years at the time of
diagnosis. Animals used for this study had ages ranging from 18 to
22 years old, which is the equivalent to ~54 to 66 years old in humans.
These animals displayed stable parkinsonian features for over 3 years
following the MPTP-treatments. A number of novel therapeutic strate-
gies successfully tested in young parkinsonian monkeys have failed to
reach their endpoint when tested clinically in patients with PD (Chu
and Kordower, 2007). Thus, we hypothesize that this failure may be the
result, at least in part, from failing to test these therapies in older an-
imals, which may represent a much more clinically relevant model for
translation.
Another focus of this study was to investigate how BOLD-activation
in the motor cortex was associated with functional changes in other
areas of the cortico-nigrostriatal loops. The results from the present
study demonstrated that both dynamic BOLD-activations and basal
glutamate levels were reduced in the primary motor cortex on the ip-
silateral side to the MPTP lesion suggesting that stronger activations
and higher glutamate levels were co-localized in the hemisphere con-
tralateral to the MPTP administration. Few nonhuman primate studies
have been conducted to directly compare these two parameters, parti-
cularly in parkinsonian monkeys. Previously, in vivo fMRI has been
used to map the brain's hemodynamic responses to neuronal stimula-
tions such as the susceptibility-based BOLD image contrast and the
change in regional CBF (rCBF) (Silva and Koretsky, 2002; Silva et al.,
1999; van Zijl et al., 1998). Results from those studies indicated that the
effects of BOLD and rCBF appeared to reflect neuronal activity (Hoge
et al., 1999; Logothetis et al., 2001; Ogawa et al., 2000; Silva and
Koretsky, 2002), and were considered to be coupled tightly with
Fig. 4. (A) Resting levels of glutamate were measured from 5 areas (2–3mm apart) in the primary motor cortex from both the left and right hemispheres. Basal
glutamate levels in the ipsilateral motor cortex were significantly lower than the contralateral motor cortex; P=0.031. K+ (100mM)- and amphetamine (250 μM)-
evoked DA release was significantly attenuated in the ipsilateral (B) putamen (Put) and (C) SNc; ***P < 0.0001 – adapted from (Quintero et al., 2011). (D)
Glutamate levels in the right (MTP-lesioned side) motor cortex were inversely correlated with phMRI signals in the right putamen. (E) BOLD-responses in the right
motor cortex were negatively correlated with dopamine levels in the right subtantia nigra after amphetamine stimulation.
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neuronal activation via the metabolic demand of associated glutamate
transportation (for a review, see Eulenburg and Gomeza, 2010). The
results from the current study support the hypothesis that BOLD-acti-
vation is associated with basal glutamate levels. In a human study using
a combined magnetic resonance spectroscopy and fMRI approach, Horn
et al. (2010) found that glutamate and resting-state functional con-
nectivity (judged by BOLD activation) were correlated in patients suf-
fering with depression. Further support for a relationship between re-
gional cortical connectivity and glutamate levels was reported by
Duncan and colleagues (Duncan et al., 2011).
The results from our study in middle-aged rhesus monkeys with
stable, long-term parkinsonism caused by MPTP administration confirm
a close relationship between BOLD activation in the cortico-nigros-
triatal loops induced by dopaminergic receptor stimulation and the
severity of parkinsonism. In addition, BOLD activation was seen to
correlate with 1) cortical levels of resting glutamate, 2) nigrostriatal
dopamine overflow, and 3) histopathologically-determined numbers of
dopaminergic neurons and terminals The results are in line with our
previous studies that showed phMRI BOLD-responses induced by do-
paminergic drugs can be used for assessing nigrostriatal dopamine
function(Zhang et al., 2006), and for differentiating PD-related from
age-related changes in basal ganglia function (Andersen et al., 2015).
Future studies will need to be carried out to advance the development
of this imaging strategy for application in humans.
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